News
11-08-2010, 10:11 PM
Amgen today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the following: a pathologic fracture, the need for radiation or surgery to ameliorate bone pathology secondary to tumor growth, or spinal cord compression.
More... (http://www.news-medical.net/news/20101108/Denosumab-superior-to-Zometa-in-preventing-SREs-in-breast-cancer-patients-with-bone-metastases-Study.aspx)
More... (http://www.news-medical.net/news/20101108/Denosumab-superior-to-Zometa-in-preventing-SREs-in-breast-cancer-patients-with-bone-metastases-Study.aspx)